NUVB vs NTLA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NUVB · Nuvation Bio$3.80 ▼ 0.26%
NTLA · Intellia Therapeutics$10.00 ▲ 5.04%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NUVB -48.7%
- NTLA +19.8%
Head to head
| Metric | NUVB | NTLA |
|---|---|---|
| Price | $3.80 | $10.00 |
| Change today | ▼ 0.26% | ▲ 5.04% |
| Market cap | $1.34B | $1.40B |
| Return, 3 months | -43.8% | -20.4% |
| Return, year to date | -57.6% | +11.2% |
| Return, 1 year | -45.6% | +21.8% |
| P/E (TTM) | – | – |
| P/B | 5.9 | 2.3 |
| P/E percentile vs own 5y | 23rd | 78th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +242.6% | -48.0% |
| Net profit growth (YoY) | +24.9% | -25.8% |
| Gross margin | 85.8% | – |
| Operating margin | -61.2% | -821.2% |
| Net margin | -67.4% | -805.7% |
| Return on equity | -49.1% | -62.6% |
| Analyst target vs. price | +258.7% | +92.0% |
| Analyst buy share | 100% | 36% |
| RSI (14) | 31 | 41 |
| 30-day volatility | 57.5% | 77.8% |
| Max drawdown, 1 year | -60.4% | -46.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NTLA is the largest of the group by market value.
- NTLA has returned the most over the past year.
- NUVB is growing revenue fastest.
- NUVB keeps the most profit per dollar of sales.
- NUVB has been the calmest stock over the last 30 days.